MASCT-I
/ HRYZ BIOTECH
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 26, 2023
MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.
(clinicaltrials.gov)
- P1 | N=22 | Completed | Sponsor: SYZ Cell Therapy Co..
Metastases • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IL10
1 to 1
Of
1
Go to page
1